.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after an average follow-up of 11 months, individuals with metastatic intestinal growths who obtained biomarker-matched treatments based on distributing growth DNA profiling showed a higher professional advantage than those obtaining incomparable treatment.